Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CD19 and CD22 CAR-T in newly diagnosed Ph- B-ALL
NCT04740203Phase 2Unknown
- Sponsor
- Zhejiang University
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19 CAR-T cells, CART22-65s in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Zhejiang University. Status: unknown.
02
Drugs
CD19 CAR-T cellsCART22-65s
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04740203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740203.